Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
Explore this paper's citation graph
Summary
The addition of gemcitabine to adjuvant fluorouracil-based chemoradiation was associated with a survival benefit for patients with resected pancreatic cancer, although this improvement was not statistically significant.
- Type
- article
- Published
- 2008-03-05
- Cited by
- 756
- References
- 39
- OpenAlex
- https://openalex.org/W2073768319
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:2214107
Keywords
Medicine, Gemcitabine, Fluorouracil, Hazard ratio, Adenocarcinoma
References
- Carcinoma of the body and tail of the pancreas: is curative resection justified?
- Chemotherapy for pancreatic cancer.
- Carcinoma of body and tail of pancreas.
- Pancreatic and periampullary carcinoma. Experience with 200 patients over a 12 year period.
- The Exocrine Pancreas.
- Protracted intravenous fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: a phase I Eastern Cooperative Oncology Group Trial.
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
- Adjuvant therapy for pancreatic cancer
- The randomization and stratification of patients to clinical trials.
- Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas
- Adjuvant therapy for pancreatic cancer: one small step forward.
- Chemotherapy in pancreatic cancer.
- A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282.
- Patterns of failure after curative resection of pancreatic carcinoma
- Continuing controversy over adjuvant therapy of pancreatic cancer.
- Carcinoma of the pancreas: Review of MGH experience from 1963 to 1973—Analysis of surgical failure and implications for radiation therapy
- Long‐Term Survival After Resection for Ductal Adenocarcinoma of the Pancreas Is It Really Improving?
- THE CONSTITUTION OF LIBERTY
- Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroœsophageal junction
- A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer.
Cited by
- Adjuvant treatment of pancreatic cancer in 2009: where are we? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009.
- Combined Modality Treatment of Resectable and Borderline Resectable Pancreas Cancer: Expert Consensus Statement
- Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium.
- The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine
- Pancreatic Intraepithelial Neoplasia and Histologic Changes in Non-neoplastic Pancreas Associated with Neoadjuvant Therapy in Patients with Pancreatic Ductal Adenocarcinoma
- Functional p38 MAPK Identified by Biomarker Profiling of Pancreatic Cancer Restrains Growth through JNK Inhibition and Correlates with Improved Survival
- Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future
- Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study)
- Effect Of Garcinol On Change In Gene Expression In Pancreatic Cancer Mouse Model
- Altered Responses to Endoplasmic Reticulum Stress in Pancreatic Cancer
- Radiotherapy of the pancreas: state of the art in 2012.
- Chemoradiation therapy: localized esophageal, gastric, and pancreatic cancer.
- Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
- Accomplishments in 2008 in the management of localized pancreatic cancer.
- Role of radiation therapy in patients with resectable pancreatic cancer.
- Estratègies terapèutiques dirigides a evitar resistències en adenocarcinoma ductal pancreàtic
- Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer
- Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets
- Radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancer
- Adjuvante und palliative Therapie des Pankreaskarzinoms
Related papers
- Gemcitabine resistance is associated with epithelial-mesenchymal transition and induction of HIF-1α in pancreatic cancer cells.
- Selenium Induces Pancreatic Cancer Cell Death Alone and in Combination with Gemcitabine
- Aberrant expression of circulating microRNAs in pancreatic cancer patients and in patients with gemcitabine resistance
- Natural Anti-Cancer Agents: Implications in Gemcitabine-Resistant Pancreatic Cancer Treatment.
- USP9X inhibition improves gemcitabine sensitivity in pancreatic cancer by inhibiting autophagy.
- Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer
- Research advances on related molecules and genes affecting the efficacy of gemcitabine for pancreatic cancer
- Lipocalin 2 may be a key factor regulating the chemosensitivity of pancreatic cancer to gemcitabine
- An antiendothelial combination therapy strategy to increase survival in experimental pancreatic cancer.
- Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine.